Special Issue

Discovery and Biosynthesis of Novel Antibiotic from *Streptomyces*

Message from the Guest Editor

This Special Issue aims to highlight the recent developments in genome-based methods and strategies focused on discovery, analysis, and manipulation the structural and regulatory genes in “orphan” biosynthetic gene clusters in order to activate or increase the production of valuable compounds, and also the heterologous expression and application of synthetic biology tools for discovery of novel antibiotics from *Streptomyces*. Manuscripts that further our understanding of recent advances in the field of antimicrobial drug discovery from other *Actinomycetes* are also welcome. **Keywords:** Antibiotics; *Streptomyces*; *Actinomycetes*; Biosynthetic pathway; Orphan gene clusters; Heterologous expression; Synthetic biology

Guest Editor

Dr. Olga Sekurova

Department of Pharmacognosy, Faculty of Life Sciences, University of Vienna, Vienna, Austria

Deadline for manuscript submissions

closed (30 November 2021)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/67497

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI